CN104873530A

CN104873530A - Anti-cancer drug composition containing amentoflavone

Info

Publication number: CN104873530A
Application number: CN201510303792.4A
Authority: CN
Inventors: 李振山; 李菲; 任广伟
Original assignee: Taishan Medical University
Current assignee: Taishan Medical University
Priority date: 2015-06-05
Filing date: 2015-06-05
Publication date: 2015-09-02

Abstract

The invention relates to an anti-cancer drug composition containing amentoflavone. The drug composition adopts the amentoflavone, swertiamarin, syringopicroside and false Chinese swertia herb as bulk drugs which are matched to prepare various dosage forms according to the conventional preparation technology. The drug composition provided by the invention has significance on preparing anti-cancer drug, especially anti-hepatoma drug, anti-lung cancer drug and anti-gastric caner drug.

Description

A kind of anticancer pharmaceutical composition containing amentoflavone

Technical field

The invention belongs to biomedicine field, relate to a kind of anticancer pharmaceutical composition containing amentoflavone.

Background technology

According in February, 2010 Ministry of Public Health statistics, annual global number of cancer deaths reaches 1,000 ten thousand.The reason of current global 1/4th human mortalities is caused by cancer, and prediction is gone down by current trend development, is owing to having suffered from cancer to the year two thousand fifty by there being the died of 1/2nd.The pernicious cancer morbidity of China, with annual 2.5-5% speed increment, has become the arch-criminal of serious harm human life.Higher with sickness rate such as pulmonary carcinoma, gastric cancer, hepatocarcinoma in the middle of various types of cancer.

It is required that the formation that blood vessel is normal structure organ betides function maintenance, and all diseases that it and human development lack of proper care and Different types of etiopathogenises causes are closely related.Tumor neovasculature is formed in tumorigenesis, transfer and recurrence and plays very important effect.As long as a series of research shows effectively Tumor suppression neovascularization, just can generate, shift and recurrence by Tumor suppression.In addition, the disease such as diabetes and rheumatic arthritis has blood vessel hyperplasia, its aberrant angiogenesis and tumor vessel closely similar.Therefore, angiogenic inhibitor also can be used for vascular proliferative disease such as treatment diabetes and rheumatic arthritis etc.In recent years, the research of people to tumor-blood-vessel growth mechanism deepens continuously, and medicine such as Avastin, Angiostatin etc. of many Antineoplastic angiogenesis are developed in succession, apply clinically.This kind of medicine not only may be used for the treatment of most of solid tumor, the prevention of tumor and the treatment of Malignancy can also be used for, simultaneously to the disease of other and associated angiogenesis as the prevention of diabetic renal papillary necrosis, rheumatic arthritis, psoriasis, hemangioma, atherosclerosis etc. and treatment, all there is certain theory and realistic meaning.

Tumor cell in tumor can be divided into two classes.One class is common tumor cell, and a class is tumor stem cell.Common tumor cell has quick division, and the sense of antagonism anticancer sensitivity, does not have the features such as self updating ability.Therefore common tumor cell can be dead after the certain algebraically of division.Tumor stem cell then has following features: remain static under normal circumstances, and not splitting status, insensitive to antineoplastic agent, has self updating ability, namely has the ability of Immortalization.In chemotherapy of tumors, a large amount of tumor cells is killed (because responsive to chemotherapeutic), but tumor stem cell can survive (because insensitive to chemotherapeutic).The recurrence of tumor is because chemotherapy of tumors medicine is invalid to tumor stem cell.The medicine effectively treating tumor stem cell is looked for be a current direction.The key of tumor eradication can not lie in and can kill common tumor cell, and be tumor eradication stem cell.

The history of Chinese medicine cancer is of long standing and well established, and existing Ramulus et folium taxi cuspidatae, Fructus seu radix camptothecae acuminatae (Fructus Camptothecae Acuminatae), arsenicum, green tea, Ganoderma, Radix Ginseng, Herba Catharanthi Rosei, Radix Asparagi, Herba Scutellariae Barbatae, Radix Semiaquilegiae etc. are for clinical anticancer so far, achieve some good effects.For a long time, people apply Traditional Thinking, theory and method research and development anticancer herbal drug, although achieve progress, produce little effect.Chinese herbal medicine becomes first-selected cancer therapy drug not yet at home and abroad so far, and the anticancer therapeutic assistant officer of existing clinical Chinese herbal medicine needs to improve further.Therefore, research and development Chinese herbal medicine cancer therapy drug is the task of top priority of the pernicious cancer for the treatment of at present, and the chemical nature illustrating endogenous low molecule tumour-inhibitory substance is the key problem of this area research.

Amentoflavone (amentoflavone) No. CAS: 1617-53-4, molecular formula C ₃₀h ₁₈o ₁₀molecular weight 538.46, antifungal (Aspergillus fumigatus, Botrytis cinerea and powder green trichoderma bacterium); Nucleoside-diphosphatase inhibitor.

Sweroside (swertiamarin swertamarin): No. CAS: 17388-39-5, molecular weight: 374.34, molecular formula: C ₁₆h ₂₂o ₁₀, this product is white flaky crystals (ethanol, chloroform, ether), bitter in the mouth, in atmosphere slightly hygroscopicity.Fusing point 113-114 DEG C, optical rotation-127 ° (c=1,96% ethanol).Be soluble in methanol, ethanol, be slightly soluble in water, be insoluble to chloroform, petroleum ether.There is effect of heat-clearing and toxic substances removing, function of gallbladder promoting stomach invigorating.

Syringopicroside (syringopicroside): No. CAS: 29118-80-7, molecular formula C ₂₄h ₃₀o ₁₁, molecular weight: 494.4884.There is antivirus action

Sweroside (sweroside): No. CAS: 14215-86-2, molecular formula: C ₁₆h ₂₂o ₉, molecular weight: 358.34.Belong to secoiridoid glycosides compound.Colourless powder, bitter in the mouth.Fusing point 113 ~ 115 °, optical rotation [α] _d26-220 ° (c=1, water).Derive from gentianaceae plant Japan Herba Swertiae bimaculatae (Szvertia japonica Makino) herb, the fruit etc. of Cornaceae plant Fructus Corni (Cornus officina lis Seib. et Zucc.).Have and protect the liver and digestion promoting function.

4 kinds of medicines structures of pharmaceutical composition of the present invention are as follows:

Amentoflavone (amentoflavone) sweroside (swertiamarin swertamarin)

Syringopicroside (syringopicroside) sweroside (sweroside)

Summary of the invention

The object of the invention is the deficiency overcoming background technology, a kind of anticancer pharmaceutical composition containing amentoflavone is provided.

The present invention is achieved through the following technical solutions:

Composition and the weight portion of the crude drug of a kind of anticancer pharmaceutical composition containing amentoflavone of the present invention are:

Amentoflavone 11-33 weight portion sweroside 16-28 weight portion syringopicroside 10-25 weight portion sweroside 30-40 weight portion.

Preferably containing an anticancer pharmaceutical composition for amentoflavone, it is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:

Amentoflavone 22 weight portion sweroside 20 weight portion syringopicroside 17 weight portion sweroside 35 weight portion.

Amentoflavone 28 weight portion sweroside 18 weight portion syringopicroside 15 weight portion sweroside 32 weight portion.

Amentoflavone 25 weight portion sweroside 23 weight portion syringopicroside 20 weight portion sweroside 36 weight portion.

A kind of anticancer pharmaceutical composition containing amentoflavone of the present invention, is characterized in that for anti-hepatocarcinoma, pulmonary carcinoma, gastric cancer.

The pharmaceutical composition of preferred a kind of anti-hepatocarcinoma, is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:

The pharmaceutical composition of preferred a kind of anti-pulmonary carcinoma, is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:

Amentoflavone 28 weight portion sweroside 20 weight portion syringopicroside 15 weight portion sweroside 32 weight portion.

The pharmaceutical composition of preferred a kind of anti-gastric cancer, is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:

A kind of anticancer pharmaceutical composition containing amentoflavone of the present invention can adopt the conventional method of galenic pharmacy to be prepared into tablet, capsule, drop pill.

This experimentation shows, pharmaceutical composition of the present invention has the effect compared with high inhibition to little S180 sarcoma of rats, and we study its impact on angiogenesis further on this basis.Blood capillary number when evaluating the most objective criterion of cancer angiogenesis degree in cancerous tissue, this experiment is by mice transplantability cancer model experiment in vivo, tumor body blood capillary labelling dyes, microvessel density shows, pharmaceutical composition of the present invention can suppress the generation of cancer blood vessel, compare with matched group, there is significant difference.The present invention measures the exercising result display that pharmaceutical composition of the present invention kills and wounds cancerous cell (HepG2, GLC, MFC), and its main manifestations is the cytotoxicity feature of concentration-dependant, and namely along with drug dose increases, inhibitory action strengthens gradually.

Detailed description of the invention

Below by specific experiment example and embodiment, a kind of anticancer pharmaceutical composition containing amentoflavone of the present invention is described further, but is not limited to the present invention.

Embodiment 1: containing the anticancer pharmaceutical composition of amentoflavone

Containing the composition of the anticancer pharmaceutical composition crude drug of amentoflavone and weight portion be:

Amentoflavone 11 weight portion sweroside 28 weight portion syringopicroside 10 weight portion sweroside 40 weight portion.

Embodiment 2: containing the anticancer pharmaceutical composition of amentoflavone

Amentoflavone 33 weight portion sweroside 16 weight portion syringopicroside 25 weight portion sweroside 30 weight portion.

Embodiment 3: containing the anticancer pharmaceutical composition of amentoflavone

Embodiment 4: containing the anticancer pharmaceutical composition of amentoflavone

Embodiment 5: containing the anticancer pharmaceutical composition of amentoflavone

Embodiment 6: the preparation of tablet

Example 3 pharmaceutical composition 30g, adds starch 65g, mixing, granulates, dry, adds microcrystalline Cellulose 5g, magnesium stearate 1g, and mixing, is pressed into 1000, obtains medicinal composition tablets of the present invention.

Embodiment 7: the preparation of capsule

Example 4 pharmaceutical composition 16.5g, adds starch 25g, mixing, granulates, and dry, granulate, adds appropriate magnesium stearate, and mixing, obtains medicament composition capsule of the present invention by encapsulated 100.

Embodiment 8: the preparation of drop pill

Taking 200g polyethylene glycol 6000 water-bath (80 DEG C) heating boils molten, add embodiment 5 pharmaceutical composition 45g, stirring, is coolant with liquid paraffin, puts in glass tubing (4*80cm), chilling temperature is 10 DEG C, drip internal-and external diameter is 7.0/2.0 (mm/mm), and drip is 2cm apart from liquid level, drips speed with per minute 50 for optimum condition, blot the condensing agent on drop pill surface with cotton, obtain medicament composition dropping pills of the present invention.

experimental example 1: pharmaceutical composition is to mice transplantability S ₁₈₀ sarcoma vascularization inhibitory action

Method: murine sarcoma S ₁₈₀tumor strain, goes down to posterity inoculation in abdominal cavity.When ascites growth is vigorous, extract ascites out, cell counting, adjustment cell concentration is 2*10 ⁷individual cells/ml, at mice oxter sc S ₁₈₀sarcoma cell, often only inoculates 0.2ml.

Laboratory animal and tumor strain: kunming mice, in age in male and female half and half, 6-8 week, body weight (20 ± 2) g, is provided by Tongji Medical College, Huazhong Science and Technology Univ.'s Experimental Animal Center.Murine sarcoma S ₁₈₀thered is provided by Wuhan University's China typical culture collection center.

Medicine: embodiment 3 pharmaceutical composition, embodiment 4 pharmaceutical composition, embodiment 5 pharmaceutical composition are respectively prepares gained by embodiment 3, embodiment 4, embodiment 5 method, lot number is respectively 20130916,20130917,20130918, is configured to 0.05g/ml normal saline solution respectively.

Treatment and grouping: 120 mices were divided into 4 groups in inoculation the same day at random: blank group, embodiment 3 pharmaceutical composition group, embodiment 4 pharmaceutical composition group, embodiment 5 pharmaceutical composition group.Embodiment 3 pharmaceutical composition group, embodiment 4 pharmaceutical composition group, embodiment 5 pharmaceutical composition group, give 25ml/kg respectively.Matched group only gives normal saline 0.2ml/.Put to death mice after treatment 10d, peel off tumor body and weigh, by formulae discovery tumour inhibiting rate: tumour inhibiting rate=(matched group average tumor weight-experimental group average tumor weight) average tumor heavy * 100% of/matched group.

Namely capillary whole blood glucose: SABC SABC method dyeing blood vessel is Wuhan doctor's moral biotech firm product with miniature blood vessel staining kit (primary antibodie behave relevant Factor VIII).Pharmaceutical composition cuts specimen after respectively organizing and peeling off with matched group tumor body, fixing, embedding, section.Section after dyed, the brown dye of endotheliocyte, blood vessel is yellowish-brown, is easy to identification.The method that the mensuration of MVD is reported by Bosari etc. is carried out, and first under low power field, chooses the abundantest region of cancer blood capillary, i.e. " focus ", then is dyed to brown blood capillary number at 400 times of field range countings, gets the meansigma methods of 3 numerical value as MVD value.The endotheliocyte of any palm fibre dye or endotheliocyte bunch, as long as separate with the blood capillary of closing on, cancerous cell or other connective tissues, be just considered as a blood vessel, although lumen of vessels often can be seen, not as the standard judging blood vessel.In order to avoid compared with the interference of trunk to counting, thicker smooth muscle is had to hold to tube wall or the blood vessel of tube chamber >8 erythrocyte area will not count.

VEGF, bFGF SABC: VEGF, bFGF immunologic combined detection reagent kit (instant) is purchased from Wuhan doctor's moral biotech firm.Positive cell is brown color, immunohistochemical staining scoring is undertaken by the method for Rahman etc., namely the standards of grading of VEGF, bFGF are: according to ratio (dyeing scope) and the staining power of pigmented cells, dyeing scope (positive cell ratio) is divided into 0-4 level, and feminine gender is 0 point; Positive cell 1%-25% is 1 point; Positive cell 26%-50% is 2 points; Positive cell 51%-75% is 3 points; Positive cell 76%-100% is 1 point.Staining power is divided into 0-3 level; Feminine gender is 0 point; The weak positive is 1 point; Moderate strength is 2 points; Strong positive is 3 points, and score adds up to last scoring.

Statistical method: use SPSS statistical software, adopts t inspection.

Result:

(1) mice with tumor is to the reaction of remedy measures and tumour inhibiting rate

Latter 6th day of inoculation, each group mice with tumor oxter transplanted tumor has Semen Glycines size, and mice is active, and diet is normal.Control group mice the 8th day posterior tuberosity bulk-growth is accelerated, and some animals torpescence, takes food poor; Treat each group of mice active, diet is normal, and hair luster is normal, and tumor bulk-growth is slow.Each pharmaceutical composition group is to mice S ₁₈₀sarcoma all has inhibitory action.In table 1

Table 1 pharmaceutical composition is to mice S ₁₈₀the inhibitory action (x ± s, n=25) of sarcoma

Group	Tumor heavy (g)	Tumour inhibiting rate (%)	P
				Matched group	1.618±0.38
Embodiment 3 pharmaceutical composition group	0.654±0.41	59.58	<0.01
				Embodiment 4 pharmaceutical composition group	0.567±0.35	64.95	<0.01
Embodiment 5 pharmaceutical composition group	0.518±0.43	67.99	<0.01

(2) pharmaceutical composition is to S ₁₈₀the impact of tumor body microvessel density

Section after the dyeing of SABC SABC method, vascular endothelial cell is by brown dye, and the visible blood capillary of matched group is distributed widely in cancerous tissue interstitial, and experimental group blood capillary is relatively rare, P<0.05, in table 2.

Table 2 pharmaceutical composition is to mice S ₁₈₀transplant the impact (x ± s, n=25) of intratumoral microvascular density

Group	Microvessel density (bar/square millimeter)
		Matched group	17.95±2.57
Embodiment 3 pharmaceutical composition group	12.23±2.23 ^*
		Embodiment 4 pharmaceutical composition group	8.32±2.14 ^*
Embodiment 5 pharmaceutical composition group	8.01±2.07 ^**

Note: compared with matched group ^*p<0.05, compared with matched group ^*p<0.01.

(3) pharmaceutical composition is to S ₁₈₀the impact that tumor body VEGF, bFGF express

Showed by immune group result, VEGF, bFGF albumen is at S ₁₈₀in high expressed in sarcoma tissue, be mainly expressed in the cytoplasm of cell.The expression of pharmaceutical composition to VEGF, bFGF has obvious inhibitory action, the results are shown in Table 3.

Table 3 pharmaceutical composition is to mice S ₁₈₀the impact (x ± s, n=25) that tumor body VEGF, bFGF express

Group	Vegf expression is marked	BFGF expresses scoring
			Matched group	5.13±0.55	4.51±0.47
Embodiment 3 pharmaceutical composition group	4.32±0.57 ^*	4.37±0.42
			Embodiment 4 pharmaceutical composition group	4.68±0.49	2.86±0.39 ^*
Embodiment 5 pharmaceutical composition group	3.29±0.51 ^*	1.92±0.36 ^**

This experimentation shows, pharmaceutical composition of the present invention is to mice S ₁₈₀the tumour inhibiting rate of sarcoma is comparatively strong, and we study its impact on angiogenesis further on this basis.Blood capillary number when evaluating the most objective criterion of cancer angiogenesis degree in cancerous tissue, this experiment is by mice transplantability cancer model experiment in vivo, tumor body blood capillary labelling dyes, microvessel density shows, pharmaceutical composition of the present invention all can suppress the generation of cancer blood vessel, compare with matched group, there is significant difference.Vascularization, namely sprout from existing blood vessel and generate new blood capillary, the coordination that this multi-step process depends on vascularization promotive factor and inhibitive factor produces.Research shows, VEGF, bFGF all have expression in multiple cancer, and VEGF, bFGF play an important role in the angiogenesis of multiple cancer.

the external anticancer test of experimental example 2 pharmaceutical composition

1. modeling method: get well-grown attached cell one bottle, with the trypsinization 5min of 0.1%-0.2%.Get collecting cell after centrifugal, with the culture fluid washed cell 1 time containing 10% calf serum, be made single cell dispersion suspension, be adjusted to every milliliter containing 60 cells.Get 5ml and inject 60min plastic culture dish, confluent cultures ware surface, makes cell be uniformly distributed, and culture dish, containing 300-500 cell, is put 37 DEG C of 5%CO by every ware ₂spend the night in incubator.Under inverted microscope, the adherent distribution situation of observation of cell, if well adherent, be evenly distributed, discard culture fluid can add and different treat reagent (treating reagent with the culture fluid preparation containing 10% calf serum), after medicine and cytosis certain hour (2-4h), remove pastille culture fluid.After fresh medium rinsing, add and can carry out clone's numeration without medicine serum free culture system liquid cultivation 10-12d.Discard culture fluid, Han ' s liquid is used to wash again 1-2 time, add the fixative of new preparation, i.e. methanol ice vinegar liquid (3:1) 3-5ml, fixing 10min, discards fixative, adds 10%Giemsa dyeing liquor and dye about 20min after drying, under 20x anatomic microscope, numeration contains the colony number (clone) of more than 50.

2. the external anticancer experimentation of pharmaceutical composition.

Method is modeling as stated above.Cell culture: human lung adenocarcinoma cell GLC (Shanghai cell research introduced), HepG2 cell lines (Shanghai cell research introduced), Mus NIH mice cell MFC (Shanghai cell research introduced).In RPM1640 (U.S. Gibco) culture fluid containing 10% calf serum, (including 0.1% penicillin, streptomycin) cultivates, 37 DEG C of 4%CO ₂for subsequent use in the incubator of saturated humidity.

Medicine: positive control cisplatin (PDD) is the product of Qilu Pharmaceutical Factory, 5-fluorouracil (5-FU) is the product of Tianjin people pharmaceutical factory, Fresh during use, and its concentration PDD is 20 μ g/ml, 10 μ g/ml, 5 μ g/ml, 5-FU are 100 μ g/ml, 50 μ g/ml, 25 μ g/ml, embodiment 3 pharmaceutical composition, embodiment 4 pharmaceutical composition, embodiment 5 pharmaceutical composition experimental group are 50 μ g/ml, 25 μ g/ml, 12.5 μ g/ml.

Drug inhibition is tested: cytotoxicity test adopts improvement mtt assay, makes 3*10 ⁵/ ml cell suspension, inserts in 96 well culture plates, every hole 100 μ L.Cancerous cell negative control group (replacing with normal saline), positive controls and embodiment 3 pharmaceutical composition group, embodiment 4 pharmaceutical composition group, embodiment 5 pharmaceutical composition group are established in experiment.Variable concentrations sample is added in 96 orifice plates respectively.Often kind of dosage 3 parallel holes.After drug effect 48h, abandon the every hole of supernatant and add MTT 10 μ l, hatch 4h for 37 DEG C, after abandoning supernatant, every hole adds dimethyl sulfoxide (DMSO) 100 μ l, micro oscillator concussion 5min, automatic elisa reading instrument surveys OD value (wavelength 570 μm), calculates medicine to the suppression ratio of cancerous cell.The mean OD value * 100% that the mean OD value that the mean OD value that cancerous cell kill rate=control wells measures-dosing group measures/control wells measures.

The analysis of morphocytology change: the cell collecting real pharmaceutical composition, PDD process, observes with phase contrast microscope and takes pictures.

Apoptotic side is fixed: cultured cell is mixed with 1*10 ⁵/ ml cell suspension, be seeded in and be placed with in 24 well culture plates of coverslip, if after normal cancerous cell negative control and PDD (10 μ g/ml), 5-FU (25 μ g/ml) and pharmaceutical composition 12 μ g/ml effect 48h, 2 times are washed with PBS liquid, fix by 10% neutral formalin, PBS washes 3 times, after hydrogen peroxide treatment, buffer 37 DEG C of labelling is hatched, and PBS washes 3 times, add biotinylated dUTP labelling again, hatch for 37 DEG C, PBS washes 3 times, and 0.5%DAB substrate reactions colour developing haematoxylin is redyed, conventional mounting, microscopy.

Statistical method: often kind of medicine does parallel assay 3 hole, asks its x ± s, adopt the variance analysis of SAS software, q checks, and each drug test group compares with negative control group.

2. result

(1) impact on cancerous cell such as pharmaceutical composition group: 5-FU, PDD, pharmaceutical composition group, to the increase with drug level of the lethality of cancerous cell, suppression ratio increases gradually (P<0.01), has pole significant difference.

Table 4 MTT method measures pharmaceutical composition to the impact of cancerous cell

(2) antitumaous effect of pharmaceutical composition: the action principle of MIT method is that MIT can by the mitochondrial mitochondrial dehydrogenase of living cells (as succinate dehydrogenase and diaphorase), be reduced into indigo Jia Za (Fornazan), dead cell or erythrocyte are then without this ability, thus available colorimetry infers survival and the propagation degree of cell.The method is simple to operate, quick, responsive, and in recent years not only for the experiment of cancer therapy drug extracorporeal sensitivity, national cancer institute has screened the method for chemotherapeutics as routine with it.We adopt mtt assay to screen PTS, shorten experimental period, and repeatability better.

The present invention measures the exercising result display that pharmaceutical composition kills and wounds cancerous cell (HepG2, GLC, MFC), and its main manifestations is the cytotoxicity feature of concentration-dependant.Namely along with drug dose increases, inhibitory action strengthens gradually.Kill capability and the 5-FU of pharmaceutical composition of the present invention are more close, slightly inferior to PDD.Apoptosis result shows, and pharmaceutical composition of the present invention can cancer cell specific induction of apoptosis effectively, and apoptotic index is more consistent with positive drug PDD, 5-FU.

Claims

1., containing an anticancer pharmaceutical composition for amentoflavone, it is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:

2. a kind of anticancer pharmaceutical composition containing amentoflavone according to claim 1, is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:

3. a kind of anticancer pharmaceutical composition containing amentoflavone according to claim 1, is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:

4. a kind of anticancer pharmaceutical composition containing amentoflavone according to claim 1, is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:

5. a pharmaceutical composition for anti-hepatocarcinoma, is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:

6. a pharmaceutical composition for anti-pulmonary carcinoma, is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:

7. a pharmaceutical composition for anti-gastric cancer, is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:

8. a kind of anticancer pharmaceutical composition containing amentoflavone according to claim 1, is characterized in that described pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet, capsule, drop pill.